Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform to treat tumors of high unmet need in ocular and urologic oncology. Its AU-011, a VDC candidate, is being developed for the first line treatment of primary choroidal melanoma, a rare disease with no drugs approved. The company also develops AU-011 in additional ocular oncology indications, including choroidal metastases. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
IPO Year: 2021
Exchange: NASDAQ
Website: aurabiosciences.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/28/2025 | $22.00 | Buy | H.C. Wainwright |
| 7/25/2024 | $21.00 | Buy | H.C. Wainwright |
| 7/27/2023 | Sector Outperform | Scotiabank | |
| 4/17/2023 | $38.00 | Buy | BTIG Research |
| 7/19/2022 | $26.00 | Mkt Outperform | JMP Securities |
| 11/24/2021 | $40.00 | Outperform | SVB Leerink |
| 11/23/2021 | $38.00 | Buy | BTIG Research |
| 11/23/2021 | Outperform | Cowen | |
| 11/23/2021 | $35.00 | Outperform | Evercore ISI |
| 11/23/2021 | $40.00 | Outperform | SVB Leerink |
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - Aura Biosciences, Inc. (0001501796) (Issuer)
4 - Aura Biosciences, Inc. (0001501796) (Issuer)
4 - Aura Biosciences, Inc. (0001501796) (Issuer)
4 - Aura Biosciences, Inc. (0001501796) (Issuer)
4 - Aura Biosciences, Inc. (0001501796) (Issuer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Aura Biosciences, Inc. (0001501796) (Issuer)
4 - Aura Biosciences, Inc. (0001501796) (Issuer)
4 - Aura Biosciences, Inc. (0001501796) (Issuer)
4 - Aura Biosciences, Inc. (0001501796) (Issuer)
4 - Aura Biosciences, Inc. (0001501796) (Issuer)
4 - Aura Biosciences, Inc. (0001501796) (Issuer)
4 - Aura Biosciences, Inc. (0001501796) (Issuer)
4 - Aura Biosciences, Inc. (0001501796) (Issuer)
4 - Aura Biosciences, Inc. (0001501796) (Issuer)
4 - Aura Biosciences, Inc. (0001501796) (Issuer)
Fastest customizable press release news feed in the world
Cadmus C. Rich, MD, MBA, as Chief Medical Officer, and Carlos Quezada-Ruiz, MD, FASRS, as Chair of the Scientific Advisory Board, bring invaluable clinical development expertise to VIS-101 ProgramThe ability to attract seasoned ophthalmology leaders highlights the compelling opportunity for VIS-101, and underscores our commitment to assembling a world-class teamVIS-101, a novel bifunctional biologic targeting VEGF-A/ANG2, has the potential to become the current standard for wet AMD, DME and RVO, and is expected to be Phase-3-ready in 2026 ROCKVILLE, Md., Nov. 20, 2025 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (NASDAQ:NBP) (NovaBridge or the Company) a global biotechnology platform compa
Aura Provides Phase 3 CoMpass Trial Completion Guidance: 2026 Enrollment Completion and Q4 2027 Topline Data Readout for the 15-Month Primary Endpoint Immune Profiling Data Reveal Bel-sar's Potential to Convert ‘Cold' to ‘Hot' Tumors, Supporting a Frontline Therapy Across the Bladder Cancer Spectrum; Phase 1b/2 Trial is on Track for Data Mid-2026 BOSTON, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today reported financial results for the third quarter ended September 30, 2025, and provided recent business highlights. "In the third quart
BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will present at the H.C. Wainwright 27th Annual Global Investment Conference on Wednesday, September 10, 2025, at 11:00 a.m. ET. The live webcast of the presentation will be available on the "Investors & Media" page under the "Events & Presentations" section of the Company's website at https://ir.aurabiosciences.com/events-and-presentations, where a replay of the webcast will be archived for 90 days following the p
Continued Clinical Program Execution in the Phase 3 CoMpass Trial in Early Choroidal Melanoma and the Phase 1b/2 Trial in Non-Muscle Invasive Bladder Cancer (NMIBC) Strengthened Balance Sheet with $75 Million Equity Financing; Cash Position Expected to Fund Operations into the First Half of 2027 BOSTON, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today reported financial results for the second quarter ended June 30, 2025, and provided recent business highlights. "We continued to focus on execution in our clinical programs in the se
BOSTON, May 15, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. ("Aura") (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the pricing of an underwritten public offering consisting of (i) 11,735,565 shares of its common stock and accompanying warrants to purchase an aggregate of 2,933,891 shares of common stock and (ii) to certain investors, pre-funded warrants to purchase an aggregate of up to 3,571,435 shares of its common stock at an exercise price of $0.00001 per pre-funded warrant, and accompanying warrants to purchase up to 892,858 shares of its common stock. The common stock and
BOSTON, May 15, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. ("Aura") (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the launch of an underwritten public offering of shares of its common stock and accompanying warrants to purchase shares of its common stock and, to certain investors, pre-funded warrants to purchase shares of common stock and accompanying warrants to purchase shares of its common stock. All of the shares of common stock, pre-funded warrants and accompanying common stock warrants to be sold in the offering will be offered by Aura. The offering is subject to market c
First Patient Enrolled in Multi-Dose Phase 1b/2 Trial of Bel-sar in Non-Muscle-Invasive Bladder Cancer (NMIBC); Initial Data at 3 Months Expected by Year-End 2025 Strengthened Leadership Team with the Appointment of Tony Gibney as Chief Financial and Business Officer BOSTON, May 15, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today reported financial results for the first quarter ended March 31, 2025, and provided recent business highlights. "Aura has started 2025 with strong momentum, making meaningful strides across both our ocular and urologi
BOSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that members of its senior management team will participate in the following upcoming investor conferences: The Citizens Life Sciences Conference on Thursday, May 8, 2025.Fireside Chat at 9:30 a.m. ET. H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ on Tuesday, May 20, 2025.Fireside Chat at 2:00 p.m. ET. TD Cowen 6th Annual Oncology Innovation Summit on Tuesday, May 27, 2025.Fireside Chat at 10:00 a.m. ET. The live webcasts of the fireside chats will
BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the appointment of Teresa Bitetti, President of the Global Oncology Business Unit at Takeda, to the Company's Board of Directors, effective March 31, 2025. "I am pleased to welcome Teresa to our Board of Directors," said Elisabet de los Pinos, Chief Executive Officer of Aura Biosciences. "She is a seasoned leader whose extensive operational and commercial experience will be instrumental as we advance our clinical pipeline across ocular and urologic oncology." "I am excit
Positive Phase 1 Trial Data in Non-Muscle Invasive Bladder Cancer (NMIBC) Presented at the 40th Annual European Association of Urology Congress; Supports Front-Line Treatment Potential Clinical Pipeline Continues to Advance with Phase 3 CoMpass Trial Actively Enrolling Phase 2 Trial in Metastases to the Choroid Initiated Cash Position Expected to Support Operations into 2H 2026 BOSTON, Mass., March 24, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today reported financial results for the fourth quarter and year ended December 31, 2024, and provide
10-Q - Aura Biosciences, Inc. (0001501796) (Filer)
8-K - Aura Biosciences, Inc. (0001501796) (Filer)
144 - Aura Biosciences, Inc. (0001501796) (Subject)
10-Q - Aura Biosciences, Inc. (0001501796) (Filer)
8-K - Aura Biosciences, Inc. (0001501796) (Filer)
8-K - Aura Biosciences, Inc. (0001501796) (Filer)
SCHEDULE 13D/A - Aura Biosciences, Inc. (0001501796) (Subject)
8-K - Aura Biosciences, Inc. (0001501796) (Filer)
424B5 - Aura Biosciences, Inc. (0001501796) (Filer)
424B5 - Aura Biosciences, Inc. (0001501796) (Filer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
H.C. Wainwright resumed coverage of Aura Biosciences with a rating of Buy and set a new price target of $22.00
H.C. Wainwright initiated coverage of Aura Biosciences with a rating of Buy and set a new price target of $21.00
Scotiabank initiated coverage of Aura Biosciences with a rating of Sector Outperform
BTIG Research resumed coverage of Aura Biosciences with a rating of Buy and set a new price target of $38.00
JMP Securities initiated coverage of Aura Biosciences with a rating of Mkt Outperform and set a new price target of $26.00
SVB Leerink initiated coverage of Aura Biosciences with a rating of Outperform and set a new price target of $40.00
BTIG Research initiated coverage of Aura Biosciences with a rating of Buy and set a new price target of $38.00
Cowen initiated coverage of Aura Biosciences with a rating of Outperform
Evercore ISI initiated coverage of Aura Biosciences with a rating of Outperform and set a new price target of $35.00
SVB Leerink initiated coverage of Aura Biosciences with a rating of Outperform and set a new price target of $40.00
Live Leadership Updates
Cadmus C. Rich, MD, MBA, as Chief Medical Officer, and Carlos Quezada-Ruiz, MD, FASRS, as Chair of the Scientific Advisory Board, bring invaluable clinical development expertise to VIS-101 ProgramThe ability to attract seasoned ophthalmology leaders highlights the compelling opportunity for VIS-101, and underscores our commitment to assembling a world-class teamVIS-101, a novel bifunctional biologic targeting VEGF-A/ANG2, has the potential to become the current standard for wet AMD, DME and RVO, and is expected to be Phase-3-ready in 2026 ROCKVILLE, Md., Nov. 20, 2025 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (NASDAQ:NBP) (NovaBridge or the Company) a global biotechnology platform compa
BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the appointment of Teresa Bitetti, President of the Global Oncology Business Unit at Takeda, to the Company's Board of Directors, effective March 31, 2025. "I am pleased to welcome Teresa to our Board of Directors," said Elisabet de los Pinos, Chief Executive Officer of Aura Biosciences. "She is a seasoned leader whose extensive operational and commercial experience will be instrumental as we advance our clinical pipeline across ocular and urologic oncology." "I am excit
Continued Enrollment in Global Phase 3 CoMpass Trial in Small Choroidal Melanoma and Indeterminate Lesions Ongoing Phase 1 Trial in Bladder Cancer Enrolling; Early Data Expected Mid-2024 Strong Cash Position Expected to Fund Operations into Second Half of 2026 BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors designed to preserve the function of the organ with cancer, today reported financial results for the first quarter ended March 31, 2024, and provided recent business highlights. "Throughout the first quarter of 2024, the Company made significant progress
This live feed shows all institutional transactions in real time.
SC 13G/A - Aura Biosciences, Inc. (0001501796) (Subject)
SC 13G/A - Aura Biosciences, Inc. (0001501796) (Subject)
SC 13G/A - Aura Biosciences, Inc. (0001501796) (Subject)
SC 13G/A - Aura Biosciences, Inc. (0001501796) (Subject)
SC 13G/A - Aura Biosciences, Inc. (0001501796) (Subject)
SC 13G/A - Aura Biosciences, Inc. (0001501796) (Subject)
SC 13D/A - Aura Biosciences, Inc. (0001501796) (Subject)
SC 13G - Aura Biosciences, Inc. (0001501796) (Subject)
SC 13G/A - Aura Biosciences, Inc. (0001501796) (Subject)
SC 13G/A - Aura Biosciences, Inc. (0001501796) (Subject)